Vevo Therapeutics logo — We are combining in vivo data and AI to find better targets...

Vevo Therapeutics

We are combining in vivo data and AI to find better targets and drugs that can treat more patients.

Founded 2022 25 employees Seed Total: $12.00M AI, Biotechnology +1

General Information

Company Name Vevo Therapeutics
Founded Year 2022
Employees 25
Industries AI, Biotechnology, Health and Wellness
Funding Stage Seed
Social

Get notified when Vevo Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Vevo Therapeutics

Vevo Therapeutics is a biotechnology startup founded in 2022, with a mission to revolutionize drug discovery using in vivo data and AI. The company's Mosaic platform is pioneering in capturing in vivo context of diseases with single-cell precision, enabling a more accurate representation of patient diversity in drug response. Vevo aims to build the world's largest in vivo atlas of drug interactions with patient cells using this platform. The company is based in San Francisco, CA and is backed by prominent investors in the life sciences and technology sectors, including Wing Venture Capital, General Catalyst, AIX Ventures, Camford Capital, and Mubadala Capital, who collectively participated in a $12.00M Seed Round investment on 08 December 2022. Vevo Therapeutics stands at the forefront of leveraging cutting-edge technology to discover novel drug targets and develop treatments with the potential to benefit a wider range of patients in the biotechnology industry. Learn more at www.vevo.ai.

Taxonomy: in vivo data, drug discovery, Mosaic platform, single-cell precision, patient diversity, in vivo atlas, genomics, computational biology, chemistry, San Francisco, investors, life sciences, technology

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 5
Investor Investor Investor Investor
•••• ••••
08 Dec 2022

Vevo Therapeutics Alternatives & Competitors

Vevo Therapeutics vs

Mapping how chemistry perturbs biology to build a virtual model of the human cell. Formerly known as...

Series A
38 employees
Biotechnology
Vevo Therapeutics vs
Pear Bio
Pear Bio United Kingdom

Patient-centered cancer precision medicine

Series A
10 employees
Biotechnology, Health Care
Vevo Therapeutics vs

Accelerating drug discovery and predicting the best cancer treatment for you!

Series A
19 employees
Biopharma, Biotechnology

FAQ About Vevo Therapeutics

We are combining in vivo data and AI to find better targets and drugs that can treat more patients.
Vevo Therapeutics was founded in 2022.
Vevo Therapeutics operates in the following industries: AI, Biotechnology, Health and Wellness.
Vevo Therapeutics has approximately 25 employees.
Vevo Therapeutics has completed 1 funding round, raising a total of $12.00M. The latest funding stage is Seed.
Top alternatives and competitors to Vevo Therapeutics include Tahoe Therapeutics, Pear Bio, BioReperia, Manifold Bio, Kuano. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vevo Therapeutics and Tahoe Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Vevo Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy